MedTrace Logo

Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment

NCT03516942 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 565

Last updated 2026-05-15

Study results available
· View outcomes & findings →

Summary

This research trial studies the financial burden in patients with stage I-III colon or rectal cancer who are undergoing treatment. Collecting data from patients about their cost and quality of life may help doctors to better understand the impact of cancer treatment on a patient?s employment and finances.

Conditions

  • Stage I Colon Cancer AJCC v8
  • Stage I Rectal Cancer AJCC v8
  • Stage II Colon Cancer AJCC v8
  • Stage II Rectal Cancer AJCC v8
  • Stage IIA Colon Cancer AJCC v8
  • Stage IIA Rectal Cancer AJCC v8
  • Stage IIB Colon Cancer AJCC v8
  • Stage IIB Rectal Cancer AJCC v8
  • Stage IIC Colon Cancer AJCC v8
  • Stage IIC Rectal Cancer AJCC v8
  • Stage III Colon Cancer AJCC v8
  • Stage III Rectal Cancer AJCC v8
  • Stage IIIA Colon Cancer AJCC v8
  • Stage IIIA Rectal Cancer AJCC v8
  • Stage IIIB Colon Cancer AJCC v8
  • Stage IIIB Rectal Cancer AJCC v8
  • Stage IIIC Colon Cancer AJCC v8
  • Stage IIIC Rectal Cancer AJCC v8

Interventions

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • ECOG-ACRIN Cancer Research Group

    lead NETWORK

Principal Investigators

  • Sheetal Kircher · ECOG-ACRIN Cancer Research Group

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-11
Primary Completion
2023-12-31
Completion
2028-09-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03516942 on ClinicalTrials.gov